Anti-LTBR antibody [EPR26096-171]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

LTBR (lymphotoxin beta receptor) also known as the TNFRSF3 is a significant protein that functions as a receptor for lymphotoxin and other related cytokines. The protein has a mass of around 62 kDa and is expressed in various tissues including lymphoid tissues and the epithelial cells of several organs. LTBR is present as a membrane-bound protein and helps mediate signaling that is important for cellular communication and function. Key interactions with ligands such as LTA and LIGHT activate signaling pathways which play roles in immune response.

Biological function summary

LTBR coordinates multiple cellular processes especially in immune regulation and homeostasis. It forms a complex with cytokines that binds to its extracellular domain triggering downstream signaling cascades. These cascades lead to activation of nuclear factor kappa B (NF-kB) which controls gene transcription and promotes survival and differentiation of immune cells. The capability of LTBR to interact with other TNF receptors expands its influence in lymphoid organogenesis and maintenance especially in maintaining the integrity of the lymphoid system.

Pathways

LTBR significantly participates in both the NF-kB and the non-canonical NF-kB pathways. These pathways are essential for regulating immune response and inflammation. Within these pathways LTBR interacts with other proteins such as TRAF3 and TRAF2 to mediate signaling processes. This arrangement allows for modulation of immune responses and is critical for recognizing and eliminating pathogens. Additionally the involvement of LTBR in immune system pathways aligns it with the functions of closely related proteins like TNF receptor superfamily members.

Associated diseases and disorders

LTBR has been implicated in autoimmune diseases and cancer. In autoimmunity aberrant signaling through LTBR may lead to inappropriate immune responses and inflammation as seen in disorders like systemic lupus erythematosus. Moreover in oncology abnormalities in LTBR signaling can influence tumor microenvironments and support tumor cell survival. Throughout these disease contexts LTBR often interacts with other risk-associated proteins such as NFKB1 highlighting its integration in complex pathological processes.